NASDAQ:AERI - Aerie Pharmaceuticals Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$39.61 -1.19 (-2.92 %)
(As of 02/20/2019 04:00 PM ET)
Previous Close$40.80
Today's Range$39.17 - $41.32
52-Week Range$32.18 - $74.75
Volume522,478 shs
Average Volume588,855 shs
Market Capitalization$1.80 billion
P/E Ratio-11.75
Dividend YieldN/A
Beta1.1
Aerie Pharmaceuticals, Inc., an ophthalmic pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma and other eye diseases. Its lead product is Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension. The company's advanced-stage product candidate is Roclatan, a once-daily eye drop to reduce IOP to treat patients with open-angle glaucoma and ocular hypertension. Aerie Pharmaceuticals, Inc. has a collaborative research, development, and licensing agreement with DSM. Aerie Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Durham, North Carolina.

Receive AERI News and Ratings via Email

Sign-up to receive the latest news and ratings for AERI and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:AERI
CUSIPN/A
Phone919-237-5300

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$3.60 per share

Profitability

Net Income$-145,100,000.00

Miscellaneous

Employees160
Market Cap$1.80 billion
OptionableOptionable

Aerie Pharmaceuticals (NASDAQ:AERI) Frequently Asked Questions

What is Aerie Pharmaceuticals' stock symbol?

Aerie Pharmaceuticals trades on the NASDAQ under the ticker symbol "AERI."

How were Aerie Pharmaceuticals' earnings last quarter?

Aerie Pharmaceuticals Inc (NASDAQ:AERI) posted its earnings results on Wednesday, August, 8th. The company reported ($1.14) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.98) by $0.16. The company had revenue of $2.42 million for the quarter, compared to analysts' expectations of $1.16 million. View Aerie Pharmaceuticals' Earnings History.

When is Aerie Pharmaceuticals' next earnings date?

Aerie Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, February 25th 2019. View Earnings Estimates for Aerie Pharmaceuticals.

What price target have analysts set for AERI?

11 brokers have issued twelve-month target prices for Aerie Pharmaceuticals' stock. Their forecasts range from $64.00 to $105.00. On average, they anticipate Aerie Pharmaceuticals' stock price to reach $79.20 in the next twelve months. This suggests a possible upside of 99.9% from the stock's current price. View Analyst Price Targets for Aerie Pharmaceuticals.

What is the consensus analysts' recommendation for Aerie Pharmaceuticals?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aerie Pharmaceuticals in the last year. There are currently 1 sell rating and 10 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Aerie Pharmaceuticals.

What are Wall Street analysts saying about Aerie Pharmaceuticals stock?

Here are some recent quotes from research analysts about Aerie Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "The FDA approval of Aerie’s lead drug, Rhopressa is a significant boost for the company. Aerie is also evaluating Rocklatan, a once-daily, quadruple-action fixed-dose combination of Rhopressa and Xalatan (latanoprost). The PDUFA (Prescription Drug User Fee Act) goal date for the completion of the FDA’s review of the Rocklatan NDA is set for Mar 14, 2019. Loss estimates have widened ahead of the Q4 earnings and the company has a negative earnings surprise in the recent quarters. While the glaucoma market holds potential, Aerie faces stiff competition from established branded and generic pharmaceutical companies, such as Novartis’ Simbrinza and Travtan, and Allergan’s Lumigan, as well as other smaller biotechnology and pharmaceutical companies. Shares have underperformed the industry in the past twelve months." (2/8/2019)
  • 2. Mizuho analysts commented, "We are including weekly IQVIA Scripts for Rhopressa below. For the week ended 02/01/2019, Rhopressa TRx increased +2.6% to 5,283 from 5,150 the prior week; and Rhopressa NRx increased +1.2% to 2,330 from 2,302 the prior week." (2/8/2019)
  • 3. Cantor Fitzgerald analysts commented, "We rate Aerie Pharmaceuticals Overweight. AERI commercializes and develops once- daily eye drops Rhopressa and Roclatan, respectively, for glaucoma. Rhopressa is the first novel drug in a market that has not seen innovation in 20 years. Valuation Summary We value Aerie based on the NPV of the cash flows associated with its glaucoma drug candidates. Our price target is $86/share." (10/2/2018)

Has Aerie Pharmaceuticals been receiving favorable news coverage?

Media headlines about AERI stock have trended neutral on Wednesday, according to InfoTrie Sentiment Analysis. The research group ranks the sentiment of media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Aerie Pharmaceuticals earned a coverage optimism score of 0.3 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 5.0 out of 10, indicating that recent media coverage is somewhat likely to have an impact on the stock's share price in the next several days.

Who are some of Aerie Pharmaceuticals' key competitors?

Who are Aerie Pharmaceuticals' key executives?

Aerie Pharmaceuticals' management team includes the folowing people:
  • Dr. Vicente J. Anido Jr., CEO & Chairman (Age 65)
  • Mr. Thomas A. Mitro, Pres & COO (Age 60)
  • Dr. Casey C. Kopczynski, Co-Founder & Chief Scientific Officer (Age 57)
  • Mr. Richard James Rubino CPA, CFO, Sec. & Treasurer (Age 60)
  • Ms. Jessica Crespo CPA, Director of Accounting

Who are Aerie Pharmaceuticals' major shareholders?

Aerie Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (7.06%), Foresite Capital Management III LLC (4.29%), Partner Fund Management L.P. (4.17%), Foresite Capital Management II LLC (3.68%), Bank of New York Mellon Corp (3.23%) and Jennison Associates LLC (2.60%). Company insiders that own Aerie Pharmaceuticals stock include Casey C Kopczynski, Foresite Capital Fund Ii, LP, Gerald D Cagle, Richard J Rubino, Thomas A Mitro and Vicente Anido Jr. View Institutional Ownership Trends for Aerie Pharmaceuticals.

Which major investors are selling Aerie Pharmaceuticals stock?

AERI stock was sold by a variety of institutional investors in the last quarter, including Frontier Capital Management Co. LLC, Partner Fund Management L.P., Orbimed Advisors LLC, Millennium Management LLC, Jennison Associates LLC, Columbus Circle Investors, Citigroup Inc. and Polar Capital LLP. Company insiders that have sold Aerie Pharmaceuticals company stock in the last year include Casey C Kopczynski, Richard J Rubino, Thomas A Mitro and Vicente Anido Jr. View Insider Buying and Selling for Aerie Pharmaceuticals.

Which major investors are buying Aerie Pharmaceuticals stock?

AERI stock was acquired by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp, Sectoral Asset Management Inc, Foresite Capital Management IV LLC, Foresite Capital Management III LLC, Foresite Capital Management II LLC, Candriam Luxembourg S.C.A., Eversept Partners LP and Rhenman & Partners Asset Management AB. View Insider Buying and Selling for Aerie Pharmaceuticals.

How do I buy shares of Aerie Pharmaceuticals?

Shares of AERI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Aerie Pharmaceuticals' stock price today?

One share of AERI stock can currently be purchased for approximately $39.61.

How big of a company is Aerie Pharmaceuticals?

Aerie Pharmaceuticals has a market capitalization of $1.80 billion. The company earns $-145,100,000.00 in net income (profit) each year or ($3.37) on an earnings per share basis. Aerie Pharmaceuticals employs 160 workers across the globe.

What is Aerie Pharmaceuticals' official website?

The official website for Aerie Pharmaceuticals is http://www.aeriepharma.com.

How can I contact Aerie Pharmaceuticals?

Aerie Pharmaceuticals' mailing address is 4301 Emperor Boulevard Suite 400, North Carolina NC, 27703. The company can be reached via phone at 919-237-5300 or via email at [email protected]


MarketBeat Community Rating for Aerie Pharmaceuticals (NASDAQ AERI)

Community Ranking:  3.4 out of 5 (star star star)
Outperform Votes:  602 (Vote Outperform)
Underperform Votes:  290 (Vote Underperform)
Total Votes:  892
MarketBeat's community ratings are surveys of what our community members think about Aerie Pharmaceuticals and other stocks. Vote "Outperform" if you believe AERI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AERI will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/20/2019 by MarketBeat.com Staff

Featured Article: Analyst Ratings Trading

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel